IGF-1 Has Plaque-Stabilizing Effects in Atherosclerosis by Altering Vascular Smooth Muscle Cell Phenotype

Jan H. von der Thüsen,* Keren S. Borensztajn,† Silvia Moimas,‡ Sandra van Heiningen,§ Peter Teeling,* Theo J.C. van Berkel,¶ and Erik A.L. Biessen¶

From the Department of Histopathology,* Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; the Center for Experimental and Molecular Medicine,† Academic Medical Center, Amsterdam, the Netherlands; the Molecular Medicine Laboratory,‡ International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy; the Department of Human Genetics,§ Leiden University Medical Center, Leiden; the Division of Biopharmaceutics,¶ Leiden/Amsterdam Center for Drug Research, Leiden; and the Department of Pathology,¶ Academic Hospital Maastricht, Maastricht, the Netherlands

Insulin-like growth factor-1 (IGF-1) signaling is important for the maintenance of plaque stability in atherosclerosis due to its effects on vascular smooth muscle cell (vSMC) phenotype. To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model. M1-polarized, macrophage-conditioned medium inhibited IGF-1 signaling by ablating IGF-1 and increasing IGF-binding protein 3, increased vSMC apoptosis, and decreased proliferation. Expression of α-actin and col3a1 genes was strongly attenuated by macrophage-conditioned medium, whereas expression of matrix-degrading enzymes was increased. Importantly, all of these effects could be corrected by supplementation with IGF-1. In vivo, treatment with the stable IGF-1 analog Long R3 IGF-1 in apolipoprotein E knockout mice reduced stenosis and core size, and doubled cap/core ratio in early atherosclerosis. In advanced plaques, Long R3 IGF-1 increased the vSMC content of the plaque by more than twofold and significantly reduced the rate of intraplaque hemorrhage. We believe that IGF-1 in atherosclerotic plaques may have a role in preventing plaque instability, not only by modulating smooth muscle cell turnover, but also by altering smooth muscle cell phenotype. (Am J Pathol 2011, 178:924–934; DOI: 10.1016/j.ajpath.2010.10.007)

Atherosclerosis is an inflammatory process,1 of which the cellular components can affect plaque stability. Thus, macrophages are generally considered to have detrimental effects on plaque stability through the elaboration of various proinflammatory factors and matrix-degrading enzymes.2,3 Conversely, an at least partially protective role has been attributed to vascular smooth muscle cells (vSMCs) due to their contribution to the size and structural integrity of the fibrous cap. The plaque content and phenotypic characteristics of plaque vSMCs are therefore considered to be important determinants of plaque stability. Hence, vSMC apoptosis has been identified as a potential contributory factor in plaque rupture.4–6 This has been corroborated by experiments in our group, in which adenovirus-mediated transfer of the proapoptotic genes p537 and FasL8 to cap smooth muscle cells induced vulnerable plaque morphology and features of plaque rupture in a murine model of atherosclerosis.

In the atherosclerotic plaque, both turnover and phenotype of smooth muscle cells are regulated by a host of local stimulatory and inhibitory signals. These include components of the extracellular matrix and locally produced paracrine and autocrine factors, but also systemically active circulating hormones such as insulin-like growth factor (IGF)-1 and IGF-2, 2 members of the insulin-like growth factor axis.9 IGF-1 in particular has received considerable attention as a potentially important factor in atherogenesis, although its overall role remains contested. On a tissue level, IGF-1, its receptor (IGF-1R), and various IGF-1 binding proteins are known to be expressed by cells in human atherosclerotic plaques, in-
including vSMCs. Clinically, serum levels of IGF-1 and its most important systemic binding protein, IGFBP-3, have been found to be correlated with carotid atherosclerosis, whereas Juul et al. have demonstrated a significantly increased risk of ischemic heart disease in patients with low serum IGF-1 and high IGFBP-3 levels. Recently, Sukhanov et al. showed that IGF-1 may have antiatherogenic properties in apolipoprotein E-deficient (ApoE−/−) mice by reducing macrophage infiltration. With respect to IGF-1 signaling in smooth muscle cells, the atherosclerotic plaque appears to harbor largely inhibitory conditions, possibly due to the immersion of these cells in the highly inflammatory milieu created by resident macrophages. Most research to date has been focused on the effects of the modulation of IGF-1 signaling on apoptosis of vSMCs, and little is known about its effect on other phenotypic parameters. Thus, in addition to influencing the level of apoptosis in plaque vSMCs, a reduction of IGF-1 signaling might also lead to impaired maintenance of the extracellular matrix of the lesional cap by these cells, thereby diminishing plaque stability.

To investigate the potential of phenotypic modulation of vSMCs by an alteration in IGF-1 signaling to achieve stabilization of the atherosclerotic plaque, we incubated murine arterial vSMCs with medium conditioned by activated macrophages, and measured the effect on various parameters of the IGF-1 system, as well as their productive and degradative capacity for collagenous matrix. The effect of IGF-1 on atherosclerosis in vivo was assessed by continuous subcutaneous administration of the IGF-1 analog Long R3 IGFI-1 in a model of accelerated atherogenesis in apoE−/− mice.

Materials and Methods

Animals

All animal work was approved by the regulatory authority of Leiden University and performed in compliance with Dutch government guidelines. Twelve- to 14-week-old female apoE-deficient mice (9× back-crossed onto C57Bl/6 background, Jackson Labs, Bar Harbor, ME) and C57Bl/6 mice (Broekman, Someren, the Netherlands) were kept on a regular dark/light cycle, and fed regular chow or a semisynthetic Western-type diet containing 15% (w/w) cacao butter and 0.25% (w/w) cholesterol (Diet W; Special Diet Services, Witham, UK).

Cell Culture

The cell culturing reagents were from Cambrex Corporation (Verviers, Belgium), the culturing equipment from Costar (Schiphol Rijk, the Netherlands), human IGF-1 and TNF-α from Sigma-Aldrich (Saint Louis, MO), and Long R3 IGFI-1 from Gropep (Adelaide, Australia). Anti-PDGF-BB neutralizing antibody was from Millipore (Billerica, MA) and used in a concentration of 20 μg/ml.

Smooth muscle cells were isolated from the aortas of C57Bl/6 mice by collagenase digestion as described previously by Michon et al. The cells were cultured in wells coated with gelatin (0.1% w/v in phosphate-buffered saline (PBS)), and maintained in culture medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% normal calf serum (NCS), penicillin (100 U/ml), streptomycin (100 μg/ml), and L-Glu (2 mmol/L) (used at passage numbers 19–30). Cells were washed 3 times with PBS, and serum starved for 4 hours before stimulation.

RAW 264.7 cells, a murine macrophage cell line, were cultured in DMEM containing 10% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 μg/ml), and L-Glu (2 mmol/L). Conditioned medium (CM) was produced as follows: RAW cells were grown to 70% confluency and then incubated with lipopolysaccharide (LPS, 15 ng/ml; Sigma) for 6 hours in medium as described above. The cells were then washed twice with PBS and subsequently allowed to proliferate for 24 hours in standard medium (containing no LPS), following which the supernatant was isolated and stored at −80°C until further use. Nonconditioned medium was used as a control. Smooth muscle cells were serum starved for 4 hours and subsequently incubated with conditioned medium or control medium for 24 hours before harvesting for gene expression and protein synthesis (quantitative PCR and Western blot) analysis.

The rates of apoptosis were inferred from a propidium iodide (PI) or PI/Annexin V assay (Santa Cruz, Heidelberg, Germany) as follows. After trypsinization, cells were centrifuged (1600 × g) for 5 minutes at 4°C, the supernatant discarded, and the pellet resuspended in PBS-EDTA (1 mmol/L). A total of 800 μl of 100% ethanol was added, and cells were fixed at −20°C. The suspension was again centrifuged (2400 × g) for 5 minutes at 4°C, and the cells were washed with PBS-EDTA 1 mmol/L. The sediment was resuspended in prodium iodide/RNase (7.5 μmol/L and 25 μg/L, respectively) in PBS-EDTA (1 mmol/L), followed by FACS (fluorescence-activated cell sorter) analysis (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ). Alternatively, resuspended cells were incubated with propidium iodide and annexin V before FACS analysis.

Cellular viability was determined by MTT assay (Sigma). In the control condition, 1 × 10⁵ cells per well were seeded onto 96-well plates in DMEM supplemented with 10% FCS. To determine the effect of CM on cell viability, 10⁴ cells per well were seeded directly in CM, or CM supplemented with the indicated concentrations of IGF-1. Cell viability was determined by incubating 0.5 mg/ml MTT directly added to the media for a minimum of 2 hours at 37°C. Subsequently, the media were aspirated, and the cells were lysed in isopropanol/0.04 N HCl. The OD₅₅₀ of this solution was determined by incubating 50 μl/ml of 3H-thymidine stock (20–25 Ci/mmol) in culture medium for 24 hours, following which the cells were washed 3 times with PBS, 0.1 M NaOH was added, and the lysate was analyzed in a beta counter (Perkin-Elmer, Boston, MA).

RNA Extraction and Real-Time Quantitative PCR

For in vitro RNA extraction, TRIZOL reagent (GibcoBRL, Gaithersburg, MD) was used according to the manufactur-
er’s instructions, and tissue RNA isolation was carried out as previously described.\(^{19}\) RNA levels were determined by the Ribogreen low-range assay (Promega, Madison, WI), with a calibration curve of 0 to 50 ng/ml tRNA in TE DEPC buffer to a concentration of 5 ng/\(\mu\)L. Real-time PCR was carried out on an ABI Prism 7700 Sequence Detector (Applied Biosystems, Foster City, CA) for quantification. Primer pairs were constructed using Primer Express 1.5 software (see Table 1).

### Table 1. Primer Pairs Used for Quantitative RT-PCR

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence</th>
<th>Template nucleotide positions</th>
<th>Product length (bp)</th>
<th>GenBank</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-1</td>
<td>Fwd 5’-TGGCTTCCGGCAGCTGATGTC-3’</td>
<td>497–516</td>
<td>79</td>
<td>AF440694</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-CATGAGCAGCGGCTCTTCTTCTG-3’</td>
<td>575–556</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGF-1-R type I</td>
<td>Fwd 5’-ACAGGCTTCTCAACTGAAACTGTAAAAC-3’</td>
<td>4865–4887</td>
<td>90</td>
<td>AF056187</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-CTTCAAGGCTGGCTGAAACTGTAATG-3’</td>
<td>4954–4932</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGFBP-3</td>
<td>Fwd 5’-CCCGTGGGCTGCAAGTATGATG-3’</td>
<td>738–759</td>
<td>73</td>
<td>NM_008343</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-AGGAAAGCTGTTGCTGACATCTTCC-3’</td>
<td>810–789</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGFBP-4</td>
<td>Fwd 5’-CAGACTTCTCCACCCACAAACAGT-3’</td>
<td>848–868</td>
<td>79</td>
<td>NM_010517</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-CAGCTTCTTCGACTACACAACA-3’</td>
<td>926–907</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM (\alpha)-actin</td>
<td>Fwd 5’-TCCCTGAGAAGAGCTGACACT-3’</td>
<td>779–801</td>
<td>120</td>
<td>NM_007392</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-GATGCCGCTGACTCCAT-3’</td>
<td>898–881</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coil3a1</td>
<td>Fwd 5’-TGCTACCGCACAGAAACTGTAAG-3’</td>
<td>1455–1475</td>
<td>75</td>
<td>M18933</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-CCCTTGCACCCCTTCTTCT-3’</td>
<td>1529–1512</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP-13</td>
<td>Fwd 5’-CAGAGCACTACTCTGAAATCTGACTCATC-3’</td>
<td>129–157</td>
<td>82</td>
<td>NM_008607</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-TCAGCTGGGAGGCTGACTGACTTT-3’</td>
<td>210–185</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP-3</td>
<td>Fwd 5’-CTCTGTAGTGTGTTGTCCTCA-3’</td>
<td>323–342</td>
<td>71</td>
<td>NM_010809</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-TCCTGTATGAGTATGGGATTTCC-3’</td>
<td>393–371</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\beta)-actin</td>
<td>Fwd 5’-AAGCCGAAAGAGCTGACACATG-3’</td>
<td>422–444</td>
<td>75</td>
<td>X03672</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-CAGCGCTGAGTGTGACTAGTA-3’</td>
<td>496–476</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36B4</td>
<td>Fwd 5’-GGACCGAGAAGACCTTCCTT-3’</td>
<td>512–531</td>
<td>85</td>
<td>X15267</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-GCAACTACACTCAGAACTTTCAAT-3’</td>
<td>596–573</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPRT</td>
<td>Fwd 5’-TTGCTCGAGAATGCTGAGAGA-3’</td>
<td>292–313</td>
<td>91</td>
<td>J00423</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-AGCAGCTGAGAACAAGACTTATAG-3’</td>
<td>382–359</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>Fwd 5’-TCCATAGGACACTTGTGATTGCC-3’</td>
<td>530–550</td>
<td>85</td>
<td>NM_008084</td>
</tr>
<tr>
<td></td>
<td>Rev 5’-TCAGCCACACGCTTCTCA-3’</td>
<td>632–615</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Western Blot

Cells were lysed in Laemmli lysis buffer, incubated for 5 minutes at 95°C, and whole-cell lysates were separated by 10% sodium dodecyl-sulfate-polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred onto immobilon-P PVDF membranes (Millipore). Membranes were incubated overnight at 4°C with primary antibodies to \(\alpha\)-actin, \(\beta\)-actin, tubulin, collagen 1A1, procollagen 1A1 and 3A1, and TIMP-1 (all Santa Cruz Biotechnology, Santa Cruz, CA), or to phospho(P)-p42/44 MAPK, P-Akt, P-mTor, phospho-p70S6K (all from Cell Signal- ing Technology, Beverly, MA) in TBS with 0.1% Tween (TBS-T). 1% BSA. All secondary HRP-conjugated antibodies were from DakoCytomation (Glostrup, Denmark). Blots were imaged using Lumilight Plus ECL substrate (Roche, Basel, Switzerland) on a GeneGnome imager (Syngene, Cambridge, UK). Signal quantification was done using the GeneTools program from Syngene, using raw volumes as measure.

### Zymography

A 7.5% SDS-PAGE denaturing gel was prepared containing 0.1 mg/ml of collagen. Specimens (25 \(\mu\)L) were added to the gel wells, which were filled with 10% sodium dodecyl-sulfate-polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred onto immobilon-P PVDF membranes (Millipore). Membranes were incubated overnight at 4°C with primary antibodies to \(\alpha\)-actin, \(\beta\)-actin, tubulin, collagen 1A1, procollagen 1A1 and 3A1, and TIMP-1 (all Santa Cruz Biotechnology, Santa Cruz, CA), or to phospho(P)-p42/44 MAPK, P-Akt, P-mTor, phospho-p70S6K, total p42/44 MAPK, total mTor, total Akt, and total p70S6K (all from Cell Signaling Technology, Beverly, MA) in TBS with 0.1% Tween (TBS-T), 1% BSA. All secondary HRP-conjugated antibodies were from DakoCytomation (Glostrup, Denmark). Blots were imaged using Lumilight Plus ECL substrate (Roche, Basel, Switzerland) on a GeneGnome imager (Syngene, Cambridge, UK). Signal quantification was done using the GeneTools program from Syngene, using raw volumes as measure.

### Cell Migration Assay

Cells were grown to 70% confluence and, before experiment, labeled for 1 hour with 10 \(\mu\)mol/L CellTracker Green in serum-free medium. The dye was fixed by a 1-hour incubation in medium with 10% FCS. Subsequently, cells were washed and detached with 2 mmol/L...
EDTA in PBS. Next, cells were resuspended in serum-free medium and transferred to 8 μmol/L pore size HTS FluoroBlock Cell Culture Inserts (BD Falcon, Franklin Lakes, NJ). CM supplemented or not with the indicated concentrations of IGF-1 or Long R3 IGF-1 was added to the bottom well. Fluorescence values representing migrating cells on the bottom side of the insert were read during 76 cycles (each cycle comprising 4 readings spanning 2 minutes) at 37°C on a BioTek Reader. The raw fluorescence data were expressed as percentage of migration toward FCS; the data were then plotted with GraphPad Prism-4 (GraphPad Software, La Jolla, CA) using nonlinear regression fit.

In Vivo Experiments

For quantitative PCR of IGF-1 signaling-related genes in aortic tissue, 5 female apoE-deficient mice were fed regular chow *ad libitum* for 12 weeks. Mice were then anesthetized by subcutaneous injection of ketamine (75 mg/kg; Eurovet, Bladel, the Netherlands), droperidol (1 mg/kg), fluanirole (0.75 mg/kg), and fentanyl (0.04 mg/kg; all from Janssen-Cilag, Tilburg, the Netherlands). Blood was drawn from the inferior caval vein for analysis of serum lipids. Subsequently, a 10-minute whole-body perfusion was performed using ice-cold phosphate-buffered saline, containing 1 mmol/L EDTA, administered by heart puncture (left ventricle). After perfusion, organs were excised, frozen in liquid N2, and kept at −80°C until RNA isolation. The aorta was prepared free of periadventitial fat in situ. The aortic arch was isolated from the base (most proximal to the heart) and severed from the descending aorta just behind the left subclavian artery. The descending aorta was harvested from the arch down to the bifurcation.

To determine the effect of continuous administration of Long R3 IGF-1 [an IGF-1 analog with an extended N-terminalsegment] on early atherogenesis or advanced atherosclerotic lesions, mice were placed by insertion of perivascular carotid collars as previously described. Sterile osmotic minipumps (Alzet, type 2004, Durect Corporation, Cupertino, CA) were placed subcutaneously under isoflurane anesthesia 1 (“early” atherosclerosis) or 5 (“advanced” atherosclerosis) weeks after collar placement, respectively. Administration of Long R3 IGF-1 (n = 11 or n = 14, respectively) or control (10 mmol/L HCl) buffer (n = 15 or n = 12, respectively) by minipumps (0.25 μg/hour) was continued for 4 weeks before harvesting. During treatment, plasma Long R3 IGF-1 levels were measured by a human ELISA kit (Gro-peg). Plasma total cholesterol levels were measured spectrophotometrically using enzymatic procedures, and triglyceride levels were quantified using a commercially available kit (Roche Diagnostics). In both assays, Precipath standardized serum (Roche, Basel, Switzerland) was used as an internal standard. Artery harvesting for histological analysis was preceded by *in situ* perfusion fixation with formalin as previously described and tissues snap-frozen in liquid nitrogen. The specimens were stored at −20°C until further use.

**Histology**

The carotid arteries were sectioned in a proximal direction from the carotid bifurcation in transverse 5-μm sections, and mounted in order on a parallel series of slides. Cryosections were routinely stained with hematoxylin (Sigma Diagnostics) and eosin (Merck Diagnostica, Darmstadt, Germany), Masson’s trichrome (Accustain kit, Sigma), and picrosiris red (Direct red 80, Sigma) according to the manufacturers’ instructions. Corresponding sections on separate slides were stained immunohistochemically with antibodies against a macrophage-specific antigen (MOMA-2, polyclonal rat IgG2b; Research Diagnostics Inc, Flanders, NJ), a-smooth muscle cell actin (clone 1A4; Sigma), or an isotype-specific control antibody. Goat anti-mouse IgG peroxidase conjugate (Nordic, Tilburg, the Netherlands) and goat anti-rat IgG alkaline phosphatase conjugate (Sigma) were used as secondary antibodies, with 3,3′-diamino-benzidine and nitro blue tetrazolium as enzyme substrates (all Sigma). The images were digitized and analyzed as previously described. The point of maximal stenosis of each vessel was determined by analysis of sections at 50-μm intervals. At this point (on average, 0.5 mm proximal to the collar), morphometry was performed using LeicaQwin software (Leica Microsystems, Wetzlar, Germany). The intimal surface area was calculated by subtracting the free lumen area from the area circumscribed by the internal elastic lamina. The intima was subdivided into a fibrocellular cap and a necrotic core on the basis of extracellular matrix staining by hematoxylin and eosin, which was confirmed by staining for collagen by picrosirus red and Masson’s trichrome. Actin-positive and MOMA-2-positive areas were determined by computer-assisted color-gated measurement and related to the total intimal surface area (Leica Qwin).

**Enzyme Linked Immunoabsorbant Assay (ELISA)**

TNFα and PDGF-BB concentrations in CM were determined by OptEIA (Pharmingen, San Diego, CA) and Quantikine (R&D Systems, Minneapolis, MN) immunoassays, respectively. IGF-1 and IGFBP-3 concentrations in plasma of the animals, conditioned medium, and VSMCs supernatant were measured using specific ELISAs (IGF-1 and IGFBP-3 Quantikine, R&D systems) according to the manufacturer’s instructions.

**Statistics**

Values are expressed as mean ± SEM. A 2-tailed Student’s t-test or 1-way analysis of variance Newman-Keuls tests were used in the comparison of continuous data. A level of *P* < 0.05 was considered significant. Frequency data analysis was carried out by means of the Fisher’s exact test.
Results

Organ Expression of IGF-1 Signaling Molecules

As expected, the liver was found to have the highest level of gene expression for IGF-1 and the primary IGF-1 binding protein in the circulation, IGFBP-3 (Figure 1). Nonetheless, detectable levels of expression of genes encoding these proteins were also found in the atherosclerotic aorta, and to a lesser extent also in isolated vSMCs. The reverse was seen for IGF-R and IGFBP-4, the genes of which were found to be more highly expressed in the aorta than in liver.

In Vitro vSMC Expression of IGF-1 Signaling Molecules

A highly significant reduction in IGF-1 (−99%) and to a lesser extent IGF-R (−62%) expression in vSMCs in culture was seen following addition of CM (Figure 2, A and B; P < 0.001 and P < 0.01, respectively). IGFBP-3 expression was markedly enhanced following incubation with CM (Figure 2C; P < 0.001), and the inverse pattern was seen with respect to IGFBP-4 (−92%; Figure 2D). To correct for potential effects of TNFα in CM, we compared the effect of CM with control medium supplemented with the equivalent concentration (7.2 ng/ml) of TNFα. Whereas TNFα reduced IGF-1 and IGFBP-4 expression significantly, it did so to a lesser extent than CM (Figure 2, A and D; P < 0.001 and P < 0.01, resp.). By contrast, TNFα had no detectable effect on IGF-R or IGFBP-3, in contrast to CM (Figure 2, B and C). In an additional experiment, vSMCs were incubated with LPS in nonconditioned medium (15 ng/ml), which had no appreciable effects on the expression of IGF-1, IGFBP-3 or IGFBP-4 compared with controls (data not shown). Supernatant of SMC contained 50.6 ng/ml of IGF-1, and less than the detection level of the ELISA used for IGFBP-3. The conditioned medium of macrophages contained 119.4 ng/ml of IGF-1 and, again, no significant IGFBP-3 (Figure 2E).

Cell Turnover Studies

CM was found to increase the fraction of vSMCs in apoptosis by more than fivefold, from 1.4% to 7.7% (P < 0.001, Figure 3A). Addition of IGF-1 was able to almost completely rescue cells from CM-induced apoptosis at a concentration of 90 ng/ml or 120 ng/ml (Figure 3B), reflected in a reciprocal increase in viability (Figure 3C). The rate of proliferation was decreased by 89% (P < 0.001, Figure 3D) following incubation with CM, but addition of IGF-1 was not found to augment proliferation (Figure 3E). Equivalent levels of TNFα did not influence apoptosis or proliferation. There was an increased potency of Long R3 IGF-1 as compared with IGF-1 on proliferation (data not shown).

Expression of Extracellular Matrix Regulating Factors

mRNA levels of α-actin and col3a1 were strongly attenuated by CM (P < 0.001 and P < 0.005, resp.), whereas this effect was also notable but less dramatic with TNFα (Figure 4, A and B). The matrix-degrading enzymes ma-
trix metalloproteinase (MMP)-13 and MMP-3 were more highly expressed after exposure to CM, again an effect that could only be partially reproduced by TNFα (Figure 4, C and D). Expression of MMP-9 was unaltered (data not shown), whereas expression of the endogenous MMP inhibitor TIMP-1 was mildly induced by CM (P < 0.001), but not by TNFα (Figure 4E). All of these effects, except TIMP-1, could be at least partially abrogated by addition of IGF-1, in a dose range from 60 ng/ml to 120 ng/ml (Figure 5, A–E). Moreover, Western blot analysis showed that supplementation of the conditioned medium with the same concentration range of IGF-1 induced a dose-dependent production of collagen 1A1, α-actin, and TIMP-1 (Figures 6, A–D), as well as procollagen 1A1 and procollagen 3A1 (Figure 6E). These effects were only partially PDGF-BB dependent, as addition of a PDGF-BB neutralizing antibody to block the effect of PDGF-BB present in CM (659.7 pg/ml) was ineffective in reverting the effect of IGF-1 on α-actin and TIMP-1 protein expression (data not shown). These results prompted us to examine the phosphorylation of Akt/Pi3K pathways, which are known to be involved in cell survival and protein synthesis. As shown in Figure 7, comparison of the phosphospecific signal with the corresponding loading control shows that addition of 120 ng/ml IGF-1 in the CM induces a rapid (already after 30 minutes) and sustained (up to 5 hours) phosphorylation of mTor, as compared with the conditioned medium supplemented with PBS. Accordingly, the phosphorylation induced by addition of IGF-1 to the CM of Akt and p70S6Kinase, which are 2 downstream mTor targets (the latter of which is also involved in protein synthesis), were also sustained for the same time frame, which suggests a robust activation induced by IGF-1 of the Akt pathway. In addition, the phosphorylation of p42/44 MAPKinase, which is a downstream target of PI3K and is known to be involved both in protein synthesis and cell survival, was also enhanced and sustained. Taken together, these results strongly suggest prolonged activation of the Akt/Pi3K pathways by addition of IGF-1 to the CM, and are consistent with our other findings of increased protein synthesis and cell survival induced by this growth factor.

**Functional Consequences of IGF-1 Supplementation to CM on VSMC migration**

We observed a reduction in collagenolytic capacity of the vSMC supernatant in a zymography assay following addition of IGF-1 at concentrations of 60 ng/ml and 120 ng/ml (Figure 8A). Functionally, using a modified Boyden chamber assay, we observed that, even at the highest concentration (120 ng/ml), a gradient of IGF-1 in CM did not enhance cell movement, whereas Long R3 IGF-1 increased cell migration to an extent comparable to the 10% FCS condition (Figure 8B).
In Vivo Effects of Long R3 IGF-1 on Early and Advanced Atherosclerosis

Plasma Long R3 IGF-1 levels were in the effective range throughout the duration of the experiments (reaching 13.1 ng/ml at the time of sacrifice), and these levels did not alter animal weight or serum glucose and lipid levels (data not shown). Long R3 IGF-1 did not significantly alter absolute plaque or media surface area in both early and advanced atherosclerosis, but was found to decrease lumen stenosis by 31% and core size by 31% (Figure 9, A–I and Figure 10A). Cap/core ratio was increased by 106.5% in early atherosclerosis, and unaltered in advanced plaques. Long R3 IGF-1 caused a trend toward an increase in ASMA (α-smooth muscle actin)-positive smooth muscle cell content in an early setting, and more than doubled ASMA content in advanced plaques. Levels of endogenous IGF-1 and IGFBP-3 were unaffected by the treatment (Figure 10, B and C).

In addition to these morphometric parameters, we also found pathophysiological evidence for increased plaque stability in the vessels of Long R3 IGF-1–treated animals in a reduced rate of intraplaque hemorrhage (Figure 11).

Discussion

Although the overall role of IGF-1 in atherosclerosis remains unclear, it has recently emerged that in the context of plaque stability, IGF-1 may have a potentially stabilizing role through its antiapoptotic effects on smooth muscle cells. IGF-1 is an important mitogenic, antiapoptotic, and promigratory factor for vSMCs. Induction of smooth muscle cell apoptosis by oxLDL, on the other hand, is mediated by down-regulation of IGF-1R, whereas overexpression of IGF-1R by adenoviral transduction can counteract oxLDL-induced apoptosis. IGF-1 is seen as an archetypal fibrogenic factor for fibroblasts in various types of wound healing and inflammatory fibrotic conditions, but its role in the modulation of smooth muscle cell phenotype remains largely unknown.

Figure 5. Effect of IGF-1 on CM-induced modulation of mRNA levels for α-actin, col3a1, MMP-13, MMP-3, and TIMP-1 in vascular smooth muscle cells (vSMCs) as measured by quantitative RT-PCR. IGF-1 attenuated the effects of conditioned medium (CM) on expression of α-actin, col3a1, MMP-13, and MMP-3 in a dose range from 60 ng/ml to 120 ng/ml (A–D). There was a nonsignificant increase of TIMP-1 (E). Data are means ± SEM, n = 3–4, and expressed as relative ratio (normalized against the control). *P < 0.05, **P < 0.01, ***P < 0.005.

Figure 6. Western blot analyses of vSMC phenotype. The effects of IGF-1 on mRNA expression were closely mirrored by stimulatory effects on protein levels of α-actin, collagen 1A1, and TIMP-1 following conditioned medium (CM) incubation (densitometric data in A–C). *P < 0.05, expressed as normalized ratio against CM, relative to household protein level (β-actin); original Western blot in (D) (on cell lysates of VSMC incubated for 24 hours in macrophage CM, or CM supplemented with 60, 90, or 120 ng/ml of IGF-1. Pictures are representative of an experiment that was repeated twice). In a separate experiment (E), procollagen 1A1 and procollagen 3A1 protein levels were also found to be up-regulated relative to household protein level (tubulin). AU, arbitrary units; vSMC, vascular smooth muscle cell.

Figure 7. Western blot analyses of supplementation of CM with IGF-1 on vSMC intracellular signaling. Effect of conditioned medium (CM) supplemented with 120 ng/ml IGF-1 (+) or PBS (−) on the phosphorylation of Akt, mTor, p70 S6 kinase, and p42/44 MAP kinase. Vascular smooth muscle cells (vSMCs) were incubated in the indicated conditions for 0 minutes, 30 minutes, 60 minutes, 120 minutes, 300 minutes, or 1440 minutes. Total Akt, mTor, p70 S6 kinase, and p42/44 MAP kinase serve as loading control.
performing in duplicate.30,31 the expression of elastin by bovine, and of collagen by in vSMCs, and IGF-1 has indeed been found to augment IGF-R
conforms to earlier human data, in which expression of was found to decrease with the age of the lesions (from 6 to 21 weeks, data not shown). In the case of descending aorta. The expression of both of these genes significantly expressed in both the ascending and the by the liver, IGFBP-3, and are primarily produced IGF-1 and its most important binding protein in the circulation (IGFBP-3) were, as expected, primarily produced in vascular smooth muscle,32 the observed effects can only be partially attributed to TNFα elaborated by LPS-stimulated macrophages in the case of IGF-1 and IGFFBP-3. Further more, a TNFα-mediated effect is unlikely concerning IGF-R and IGFFBP-3. Other macrophage-derived cytokines and non-cytokine mediators have also been found to play an important role in the regulation of the expression of IGF-1, IGFR1, and the IGFBPs.11,33 Whatever the role of these individual factors in the regulation of IGF-1 signaling may be, the overall effect appears to be almost completely inhibitory toward IGF-1 signaling. The latter was confirmed in
compared with nondiseased arteries.16,17 The decrease in IGFBP-4 with maturation of lesions is unexpected, however, and may be partly explained by the fact that IGFBP-4 is primarily produced by vSMCs in the plaque. It is especially the vSMC population that is reduced in advanced plaques, concomitantly conferring an unstable plaque phenotype. Alternatively, the macrophage-rich milieu of the plaque may selectively attenuate IGFBP-4, as confirmed in our in vitro studies.

In vitro, medium conditioned by LPS-stimulated, and thus M1-polarized, murine macrophages was found to influence several aspects of IGF-1 signaling in vSMCs. The overall balance of these effects could be seen as inhibitory with a decreased expression of IGF-1 and IGF-R and an increase in IGFBP-3, albeit partly offset by a decrease in IGFBP-4. It remains to be clarified as to what relative extent these effects can be attributed to specific cytokines or other, possibly yet undefined, macrophage-derived intercellular mediators. Thus, although TNFα is both a known major proatherogenic molecule and an effective modulator of IGF-1 and IGFBP-3 expression in vascular smooth muscle,32 the observed effects can only be partially attributed to TNFα elaborated by LPS-stimulated macrophages in the case of IGF-1 and IGFBP-4. Furthermore, a TNFα-mediated effect is unlikely concerning IGF-R and IGFFBP-3. Other macrophage-derived cytokines and non-cytokine mediators have also been found to play an important role in the regulation of the expression of IGF-1 signaling may be, the overall effect appears to be almost completely inhibitory toward IGF-1 signaling. The latter was confirmed in

Rat intestinal smooth muscle cells have been shown to up-regulate expression of IGFBP-3, -4, and -5 and of type I collagen following exposure to IGF-1.28–30 Also, IGF-1 induces lower levels of collagenase activity in colonic smooth muscle cells, which could affect the turnover of extracellular matrix by inhibiting the degradation side of the equilibrium.29 Similar effects could conceivably occur in vSMCs, and IGFBP-1 has indeed been found to augment the expression of elastin by bovine, and of collagen by porcine vSMCs, respectively.30,31

We speculated that the pro-oxidant and proinflammatory extracellular milieu prevailing in the atherosclerotic plaque could play a role in the down-regulation of IGF-1 signaling that has been described in previous studies.16,17 and that interaction with another main cellular plaque constituent, the macrophage, could be of special interest. In this study, we initially confirmed the expression of various components of the IGF-1 signaling pathway in murine atherosclerotic aortas. Thus, although IGF-1 and its most important binding protein in the circulation (IGFBP-3) were, as expected, primarily produced by the liver, IGFR and IGFBP-4 were also found to be significantly expressed in both the ascending and the descending aorta. The expression of both of these genes was found to decrease with the age of the lesions (from 6 to 21 weeks, data not shown). In the case of IGFR, this conforms to earlier human data, in which expression of IGFR was found to be reduced in atherosclerotic vessels

![Figure 8](image)

Figure 8. Functional assays of vSMCs. There was an overall reduction of collagenolytic activity of IGF-1–treated vSMCs as measured by zymography (A, arrow, lighter shade indicates more collagen break-down), compared with CM containing no IGF-1. B: Cell migration assay of vascular smooth muscle cells (vSMCs) toward medium containing 10% FCS (condition FCS), conditioned medium (CM), or conditioned medium supplemented with the indicated concentrations of IGF-1 or Long R3 IGF-1. Results represent the mean ± SEM (n = 3) and are representative of 2 independent experiments performed in duplicate.

![Figure 9](image)

Figure 9. Morphology of collar-induced plaques. Long R3 IGF-1 led to a 51.3% reduction in lumen stenosis, expressed as intima/lumen ratio (C; control, n = 15; Long R3 IGF-1, n = 11; representative hematoxylin and eosin (HE) stains in A and B (magnification ×1000) and a 31.1% reduction in core size (F, **P < 0.01). D and E: Representative trichrome stains of lesional caps (marked with an asterisk, magnification ×400) in early atherogenesis. Representative ASMA-stained advanced plaques are depicted in (G and H, arrows indicate positive staining in the lesional cap). Quantitative assessment showed a more than twofold increase in ASMA-positive smooth muscle cell content in advanced plaques (I; control, n = 12; Long R3 IGF-1, n = 14). Data are means ± SEM.
cell turnover experiments, in which CM increased apoptosis by more than fivefold. This effect was not attributable to TNFα and may be at least partially mediated by attenuated IGF-1 signaling, as addition of IGF-1 substantially counteracted the effect of CM on apoptosis. Furthermore, CM virtually abolished proliferative activity in vSMCs, whereas TNFα had no effect.

Collagen deposition in the later stages of atherosclerosis is required for structural support in the plaque cap to prevent the development of unstable lesions.34 The effect of MMPs on plaque progression may be bimodal depending on their relative activity in permitting migration of destabilizing (macrophage) or stabilizing (vSMC) cells into the plaque, and destabilization of plaques due to the degradation of lesional matrix.35–37 Various MMPs have been implicated in plaque destabilization, including MMP-1,38 MMP-339 and MMP-9.37,40 From the oncology field, we have in recent years learned that IGF-1 can influence the expression of various matrix-degrading enzymes by tumor cells.41–43 The influence of IGF-1 on the expression of MMPs in the atherosclerotic plaque, however, remains largely uncharted. Risinger et al have found IGF-1 to have a stimulatory effect on MMP-2 production by vSMCs.44 By contrast, growth hormone replacement has been shown to decrease plasma levels of MMP-2 and MMP-9 in growth hormone–deficient individuals, an effect that is thought to be mediated by IGF-1 and to contribute to the reduction in vascular mortality in these patients.45 In our study, the overall effect of CM was found to be inhibitory toward collagen production and procollagenolytic, with CM effecting a decrease in the expression of α-actin and Col3a1 and an increase in the collagenolytic enzymes MMP-13 (the main interstitial murine collagenase, functionally equivalent to human MMP-1) and MMP-3. These effects were to some extent attributable to TNFα, but counteracted by IGF-1. CM caused a minor increase in expression of TIMP-1, but IGF-1 administration further enhanced the expression of this endogenous inhibitor of metalloproteinase activity. On balance, the effects of IGF-1 were anticollagenolytic, as evidenced by zymography data. A direct stimulation of migratory capacity of vSMCs by IGF-1 has previously been described,46 and to further examine the functional consequences on addition of IGF-1, or Long R3 IGF-1, we used a modified Boyden chamber assay. Interestingly, we observed that, although Long R3 IGF-1 restored cell migration to a level similar to 10% FCS in this assay, IGF-1 added to CM did not induce a significant difference as compared to the CM condition. As we have also shown, by means of ELISA, that IGFBP-3 levels in conditioned medium and vSMC supernatant are negligible, the increased effect on migration by Long R3 IGF-1 is likely to be independent of its increased bioavailability in vivo (due to the much reduced affinity of Long R3 IGF-1 for inhibitory IGFBP-3).

Figure 10. Morphometric data of collar-induced plaques. Morphometric data are summarized in tabular format in A. Concentration of IGF-1 and IGFBP3 in plasma of control of Long R3 IGF-1 treated mice as measured by ELISA in the early atherosclerosis experiment are represented in B and C. Long R3 IGF-1 does not change the plasma levels (ng/ml) of IGF-1 and IGFBP3 in the plasma measured. Data are mean ± SE of n = 15 mice in the group Long R3 IGF-1 and n = 9 mice in the control group.

Figure 11. Effect of Long R3 IGF-1 on plaque stability. Long R3 IGF-1 treatment significantly reduced the occurrence of intraplaque hemorrhage in all animals analyzed [A and B, representative hematoxylin and eosin (HE) stains (magnification ×100), hemorrhage marked with an arrow]. When analyzed in a 2 × 2 contingency table with the aid of Fisher’s exact test, this effect was indeed significant (C; 4% vs. 16%, respectively).
There is an apparent lack of consistency in the individual findings of differential expression with respect to phenotype modulation by IGF-1, as on the one hand, these may be seen as typical of a differentiated phenotype (increased α-smooth muscle actin expression) and on the other of a synthetically active, migratory phenotype, as described above. This could be due to the concomitant up-regulation of contractile cytoskeletal proteins through activation of the PI3 kinase pathway and induction of a synthetic phenotype by activation of the MAPK pathway, as we found both of these pathways to be activated by addition of IGF-1.

In vivo, we found divergent, largely stabilizing IGF-1-mediated effects in different stages of atherosclerosis. In early atherosclerosis, Long R3 IGF-1 was seen, not only to decrease plaque burden by significantly reducing lumen stenosis, but also to alter plaque morphology, by decreasing necrotic core size and increasing the cap/core ratio, which is generally considered to be a favorable indicator of plaque stability. 34 In advanced plaques, as is perhaps to be expected due to the already large size and mature, complex morphology of these lesions, Long R3 IGF-1 did not have an effect on overall plaque burden or cap size. It did, however, increase the content of ASMA-expressing smooth muscle cells in the plaque, which again could be viewed as a sign of improved plaque stability. This is corroborated by the fact that the rate of intraplaque hemorrhage was significantly reduced by treatment with Long R3 IGF-1. These findings are in line with the skewing toward a stabilizing vSMC phenotype suggested by the in vitro data.

Several issues should be kept in mind when interpreting the data. First, one might argue that macrophage CM is a complex mixture of components, which might render it difficult from which to gain significant mechanistic insights into the observed effects. This model is, however, commonly accepted to simulate the microenvironment of the atherosclerotic milieu for in vitro experiments and has been validated by different groups in a variety of studies. Several factors produced by macrophages in the atherosclerotic plaque have been found to modulate IGF-1 signaling. This, for instance, identified ox-LDL 16,17 and TNFα 32 as potential culprits in the modulation of IGF-1 in atherosclerotic lesions.

Second, for quantitative assessment of IGF-1 signaling-related proteins in tissue homogenates, we used the RT-PCR approach rather than protein measurement. This was motivated by the fact that the targets of interest are likely to be present at relatively low levels in the various murine tissues, which due to their sheer size are likely to contain at best only modest amounts of protein, in practicality often precluding their quantitative detection by Western blot/ELISA. Also, rather than determining absolute levels of different proteins, we were primarily interested in delineating relative variation in organ-specific expression patterns for defined targets. We thus specifically opted for this approach as we have previously found RT-PCR to be a valuable tool in correlating, though admittedly not equating, to relative expression levels in such experiments. 19,47,48

Finally, one might consider whether a meaningful morphometric analysis of the plaque can be performed on parameters like cap/core ratio. Relative thinning of the cap and an increase in the lesional necrotic core are (in addition to inflammation) currently seen as the best histological indicators of plaque vulnerability to rupture in humans. 49 In previous studies of murine carotid plaques, we have found that the determination of the cap/core ratio is highly reproducible, primarily due to the use of ancillary stains such as Masson’s trichrome and picrosirius red, which highlight the collagenous areas of the lesion. 7,8,37,48 The thus derived cap/core ratio was found to show close correlation with signs of plaque rupture in a model of p53-induced plaque destabilization. 7 We therefore believe that this is a technique that, in our hands, yields reproducible and biologically relevant results.

In conclusion, we believe that the above results indicate that IGF-1 in atherosclerosis may have a role in preventing plaque instability, not only by modulating smooth muscle cell turnover toward a proapoptotic and antiproliferative state, but also by skewing the balance of collagen-rich matrix production and degradation toward a more stable extracellular compartment. Although potentially detrimental in long-term use due to its alleged procarcinogenic effects, 50 IGF-1 treatment may thus hold promise in short-term plaque phenotype modulation, especially when combined with targeting strategies aimed at specifically directing treatment to the vasculature.

References


